EGFR and colorectal carcinoma: EGFR (HER-1 or erbB-1) is the most important therapeutic target in CRC patients in the absence of KRAS/NRAS mutations (228) and sex differences in CRC survival have been shown for specific germline polymorphisms within the EGFR gene (229).